Kyverna Therapeutics, Inc. (KYTX)

NASDAQ: KYTX · IEX Real-Time Price · USD
28.19
+0.68 (2.47%)
Feb 28, 2024, 2:05 PM EST - Market open
2.47%
Market Cap 1.15B
Revenue (ttm) 282,000
Net Income (ttm) -48.20M
Shares Out 40.82M
EPS (ttm) -1.18
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 186,816
Open 27.51
Previous Close 27.51
Day's Range 27.51 - 28.63
52-Week Range 26.04 - 30.50
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About KYTX

Kyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our goal is to bring disease-modifying therapeutic benefits to patients suffering from autoimmune diseases through our patient-centered approach, our broad platform, our insights into treating immune disorders and the learnings from successful application of cell therapy in other areas of medicine. Our cell therapy approach to the treatment of autoimmune diseases is supported ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Feb 8, 2024
Employees 84
Stock Exchange NASDAQ
Ticker Symbol KYTX
Full Company Profile

Financial Performance

Financial Statements

News

Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

EMERYVILLE, Calif. , Feb. 12, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for patients s...

15 days ago - PRNewsWire

Gilead-backed Kyverna Therapeutics valued at $1.4 bln in stellar debut

Shares of Kyverna Therapeutics jumped 55.7% in their market debut on Thursday, giving the biopharmaceutical company that is backed by Gilead Sciences a market capitalization of $1.4 billion.

Other symbols: GILD
20 days ago - Reuters

Kyverna Therapeutics to raise $319 million in upsized IPO

Gilead-backed Kyverna Therapeutics on Wednesday said it will raise $319 million at a valuation of $898.1 million in an upsized U.S. initial public offering (IPO).

20 days ago - Reuters

Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering

EMERYVILLE, Calif. , Feb. 7, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for patients su...

20 days ago - PRNewsWire

Gilead-backed Kyverna Therapeutics aims for $857.3 mln valuation in upsized IPO

Kyverna Therapeutics expects up to $857.3 million valuation in its U.S. initial public offering (IPO), the biotechnology company said on Tuesday as it raised its offering.

Other symbols: GILD
22 days ago - Reuters

Kyverna Therapeutics targets up to $711 mln valuation in US IPO

Biotechnology company Kyverna Therapeutics said on Thursday it was aiming for a market valuation of up to $711 million in its U.S. initial public offering (IPO).

27 days ago - Reuters

Autoimmune disease biotech Kyverna Therapeutics files for a $100 million IPO

Kyverna Therapeutics, a Phase 2-ready biotech developing cell therapies for autoimmune diseases, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering.

6 weeks ago - Renaissance Capital

Kyverna Therapeutics IPO Registration Document (S-1)

Kyverna Therapeutics has filed to go public with an IPO on the NASDAQ.

6 weeks ago - SEC

Alto, Kyverna Join Growing Number of Biotech IPO Filings in 2024

Alto Neuroscience and Kyverna Therapeutics are following in the footsteps of CG Oncology, Metagenomi and Arrivent in seeking initial public offerings this year.

6 weeks ago - BioSpace

Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in the Treatment of Patients With Refractory Myasthenia Gravis

Kyverna Therapeutics, Inc. (Kyverna), a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for...

2 months ago - PRNewswire